Abstract
Background Coagulopathy and associated bleeding and venous thromboembolism (VTE) are major causes of morbidity and mortality in patients with acute leukemia. The underlying mechanisms of these complications have not been fully elucidated.
Objectives To evaluate the associations between biomarker levels and bleeding and VTE in acute leukemia patients.
Patients/Method We examined plasma levels of activators, inhibitors and biomarkers of the coagulation and fibrinolytic pathways in patients ≥18 years with newly diagnosed acute leukemia compared to healthy controls. Multivariable regression models were used to examine the association of biomarkers with bleeding and VTE in acute leukemia patients. The study included 358 patients with acute leukemia (29 acute promyelocytic leukemia [APL], 253 non-APL acute myeloid leukemia [AML] and 76 acute lymphoblastic leukemia [ALL]), and 30 healthy controls.
Results Patients with acute leukemia had higher levels of extracellular vesicle (EV) tissue factor (TF) activity, phosphatidylserine-positive EVs, plasminogen activator inhibitor-1 (PAI-1), plasmin-antiplasmin complexes, cell-free DNA and lower levels of citrullinated histone H3-DNA complexes compared to healthy controls. APL patients had the highest levels of EVTF activity and the lowest levels of tissue plasminogen activator among the acute leukemia patients. There were 41 bleeding and 37 VTE events in acute leukemia patients. High EVTF activity was associated with increased risk of bleeding (sHR 2.30, 95%CI 0.99-5.31) whereas high PAI-1 was associated with increased risk of VTE (sHR 3.79, 95%CI 1.40-10.28) in these patients.
Conclusions Our study shows alterations in several biomarkers in acute leukemia and identifies biomarkers associated with risk of bleeding and VTE.
Essentials
The mechanisms of acute leukemia-associated bleeding and thrombosis have not been elucidated.
We measured plasma biomarkers of coagulation and fibrinolysis in acute leukemia patients.
Biomarkers of the coagulation and fibrinolytic pathways are altered in acute leukemia patients.
EVTF activity is associated with bleeding, and PAI-1 is associated with VTE in acute leukemia.
Competing Interest Statement
RG has served as a Consultant for Alexion and Sanofi, and in Advisory Board for Sanofi. The other authors declare no competing financial interests.
Funding Statement
This study was supported by the National Heart, Lung, and Blood Institute (N.M. 1R35HL155657) and the John C. Parker Professorship (N.M.). RG received research funding from the National Heart, Lung, and Blood Institute (K08 HL159290) and the American Society of Hematology. We thank Amanda Mullen for assistance with sample banking and retrieval.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted with the approval of the institutional review board at the University of Alabama at Birmingham (160420008) and informed consent was obtained according to the Declaration of Helsinki. The transfer to the University of North Carolina at Chapel Hill and measurement of biomarkers was approved by the Institutional Review Board of the University of North Carolina at Chapel Hill (21-0554).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
